She added that some of the medications and dosages including oral semaglutide, dulaglutide, 0.6 mg liraglutide and 1 mg and 2 mg injectable semaglutide have not yet been approved by the FDA for the treatment of obesity and are more likely to have been prescribed for diabetes management. Perspective Back to Top A huge population was studied (413,000) that compared the effects of different weight loss medications
Low-quality evidence from another trial that compared the effect of ALCAR (1.5 g/day) with that of methylcobalamin (1.5 mg/day) for 24 weeks suggested no difference between treatments regarding the extent of functional disability (using the Neuropathy Disability Scale) or measures of symptom quality and severity (using the Neuropathy Symptom Scale) (89)
There are other reliable resources, too, which are considered quite helpful
Through this engagement, we are able to perform additional research and generate new genetic insights that are made available to our members
11.5 Who Should Be Monitored More Closely Monitoring becomes more relevant when: Weight loss exceeds 1520% Appetite suppression leads to persistent under-eating GI symptoms persist Pre-existing marginal status exists Combination therapy (e.g., metformin) is used Older adults are treated Oversight should be proportional to risk
Chief findings: The trial withdrawal rate was 6% (n=72) with 22 receiving semaglutide 0.5 mg withdrawing, 13 receiving dulaglutide 0.75 mg withdrawing, 21 receiving semaglutide 1.0 mg withdrawing, and 16 receiving dulaglutide 1.5 mg withdrawing) The mean percentage HbA1c reduction from the mean overall baseline was by 1.5 (SE 0.06) percentage points with semaglutide 0.5 mg versus 1.1 (0.05) percentage points with dulaglutide 0.75 mg (estimated treatment difference [ETD] -0.40 percentage points [95% CI -0.55 to -0.25]
